Evaluation and Management of Elevated Liver Enzymes After Discontinuing Mili
Discontinue any consideration of restarting Mili and conduct a comprehensive hepatic evaluation to identify the underlying cause of elevated liver enzymes, as combined hormonal contraceptives containing ethinyl estradiol are contraindicated in patients with liver disease. 1
Immediate Assessment
The first priority is determining whether the liver enzyme elevation is related to prior Mili use or represents a separate hepatic process that has emerged since discontinuation:
Check for hepatocellular adenomas (HCAs): Obtain hepatic imaging (ultrasound, CT, or MRI) to evaluate for HCAs, as estrogen-containing contraceptives are strongly associated with these benign liver tumors. 2, 1 While HCAs typically regress after discontinuation of estrogen-containing contraceptives, they can persist and may have caused the enzyme elevation. 2
Assess for viral hepatitis: Test for hepatitis A, B, and C serologies, as acute or chronic viral hepatitis is a common cause of elevated transaminases and would represent an absolute contraindication to future estrogen-containing contraceptive use. 1
Evaluate for drug-induced liver injury: Review all medications, supplements, and herbal products the patient has taken in the past 6 months, as many agents can cause hepatotoxicity. 1
Screen for metabolic liver disease: Obtain fasting lipid panel, hemoglobin A1c, and consider evaluation for non-alcoholic fatty liver disease (NAFLD), particularly if the patient has risk factors such as obesity or polycystic ovary syndrome. 2
Laboratory Workup
Obtain the following tests to characterize the pattern and severity of liver injury:
Complete hepatic panel: AST, ALT, alkaline phosphatase, total and direct bilirubin, albumin, total protein, and prothrombin time/INR. 1, 3 The pattern of elevation (hepatocellular vs. cholestatic) will guide further evaluation.
Additional markers: Consider gamma-glutamyl transferase (GGT), which can help distinguish hepatic from bone sources of alkaline phosphatase elevation.
Critical Contraindications to Future Estrogen Use
The FDA labeling for Mili explicitly contraindicates use in patients with: 1
- Acute viral hepatitis or severe (decompensated) cirrhosis
- Benign or malignant liver tumors (including HCAs)
- Any acute or chronic liver function disturbance until markers return to normal and COC causation has been excluded
Alternative Contraception Recommendations
Given the elevated liver enzymes, future contraceptive counseling should prioritize non-estrogen options:
Copper IUD: This is the preferred option as it is hormone-free, highly effective (<1% failure rate), and has no hepatic contraindications. 2 It is effective for at least 10 years and does not rely on patient adherence.
Levonorgestrel IUD: This progestin-only option is acceptable as no liver-related risks are anticipated given the lack of estrogen. 2 It is effective for 3-5 years with a <1% failure rate.
Progestin-only pills or implants: These are acceptable alternatives in patients with liver disease, though data on specific liver conditions are limited. 2 The subcutaneous implant offers superior efficacy and convenience compared to daily pills.
Barrier methods: Should be used in combination with any method other than long-acting reversible contraceptives given their higher failure rates. 2
Common Pitfalls to Avoid
Do not restart estrogen-containing contraceptives until liver enzymes have normalized, the underlying cause has been identified and resolved, and hepatic imaging has excluded HCAs or other structural lesions. 1
Do not assume the enzyme elevation is simply a residual effect of prior Mili use without thorough evaluation, as this could miss serious underlying liver disease. 1
Do not use emergency contraception containing estrogen if needed urgently; the copper IUD is the most effective option (<1% failure rate) and is safe in liver disease. 2 Progestin-only emergency contraception is also acceptable.
Follow-Up Strategy
Repeat liver enzymes in 4-6 weeks after initial evaluation to assess trajectory (improving, stable, or worsening).
If enzymes normalize and no structural lesions are found, the patient may have experienced transient drug-induced hepatotoxicity from Mili, though this should be a diagnosis of exclusion. 1
If enzymes remain elevated or worsen, refer to hepatology for specialized evaluation and possible liver biopsy. 1